Cancer Drug Combo Shows Promise for Aggressive Endometrial Cancer Subtype

Researchers have identified a promising new treatment approach for an aggressive form of endometrial cancer that typically resists standard therapies. This cancer subtype, characterized by specific genetic markers including p53 mutations and high chromosomal instability, affects thousands of women annually and has historically poor outcomes.

The study tested a combination of two targeted drugs: olaparib, which blocks DNA repair in cancer cells, and pembrolizumab, which helps the immune system attack tumors. Twenty-five patients with recurrent disease received this combination therapy in a phase II clinical trial.

Results showed a 32% overall response rate, with eight patients experiencing significant tumor shrinkage or complete disappearance. Responses lasted an average of 11 months, and patients lived a median of 16.5 months overall. The treatment was generally well-tolerated with no unexpected side effects.

Crucially, the research revealed that patients whose tumors had defective DNA repair mechanisms were more likely to respond, suggesting a path toward personalized treatment selection. This finding could help doctors identify which patients would benefit most from this combination.

While these results represent meaningful progress for a difficult-to-treat cancer, important limitations remain. The study was small, and most patients still experienced disease progression relatively quickly. Additionally, the treatment only worked for a subset of patients, highlighting the need for better biomarkers to predict response. Future larger studies will be needed to confirm these findings and refine patient selection strategies.